Drug-resistant TB in India remains a treatment challenge despite improving tuberculosis outcomes, according to WHO's latest report.
Zealand Pharma is seeking pharmaceutical partnerships for its rare disease assets as it shifts investment towards obesity drug development.
India is considering changes to attract multinational pharmaceutical companies for early-stage drug research while protecting clinical trial participants.
Lupin's ranibizumab biosimilar enters Europe through Sandoz, expanding the Indian drugmaker's international ophthalmology business.
Alembic Pharmaceuticals is banking on its upcoming US drug launch pipeline to sustain strong growth as competition and pricing pressure reshape the generics market.
Amgen's experimental drug dazodalibep has delivered positive Phase 3 results, offering new possibilities for Sjogren's disease treatment.
Temple wearable technology is attracting medical scrutiny as doctors question whether its brain blood flow monitoring claims stand up to scientific examination.
Pfizer partners with Blackstone to secure USD 1.5 billion in funding, accelerating development of its monthly obesity drug berobenatide.
Novo Nordisk commits USD 200 million to strengthen diabetes care through long-term partnerships, prevention programs and healthcare access in developing countries.
Johnson & Johnson (J&J) has taken another significant step in expanding Caplyta’s bipolar treatment potential, securing its second positive Phase 3 trial result for bipolar mania.